The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - IDEAYA Biosciences; Loxo
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Solti
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - START
Other Relationship - Roche
 
Consulting or Advisory Role - Lilly (Inst)
Research Funding - AstraZeneca (Inst); Genentech (Inst); Lilly (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
Other Relationship - Roche
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).
 
Heather M. Moore
Employment - Genentech; Pfizer (I)
Stock and Other Ownership Interests - Roche
 
Valentina Boni
No Relationships to Disclose
 
Meritxell Bellet
Honoraria - Lilly; Novartis; Pfizer
Consulting or Advisory Role - Lilly; Novartis
Speakers' Bureau - Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Roche
 
Begoña Bermejo De Las Heras
Consulting or Advisory Role - MSD; Roche
Speakers' Bureau - MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
Other Relationship - Roche
 
Maria Gión Cortés
No Relationships to Disclose
 
Catherine Oakman
Other Relationship - Roche
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Other Relationship - Roche
 
Xuan Bich Trinh
Other Relationship - Roche
 
Duncan Wheatley
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
Other Relationship - Roche
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BluePrint Medicines; Bristol-Myers Squibb; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Synthon; Taiho Pharmaceutical
Research Funding - ADC Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical
 
Peter Kabos
No Relationships to Disclose
 
Elgene Lim
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Travel, Accommodations, Expenses - Lilly
 
Thierry Velu
Other Relationship - Roche
 
Ciara Metcalfe
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Patents, Royalties, Other Intellectual Property - Genentech
Other Relationship - Roche
 
Mary R. Gates
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Other Relationship - Roche
 
Ching-Wei Chang
Employment - Genentech
Stock and Other Ownership Interests - Roche
Other Relationship - Roche
 
John Bond
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Other Relationship - Roche
 
Leonard D Goldstein
Employment - Genentech; Merck (I)
Stock and Other Ownership Interests - Merck (I); Roche
Patents, Royalties, Other Intellectual Property - Genentech
Other Relationship - Roche
 
Jennifer O'Hara Lauchle
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Patents, Royalties, Other Intellectual Property - Genentech; Genentech (Inst)
Other Relationship - Roche
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)